• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

设计罕见小儿神经退行性疾病的药物研发计划。

Designing a plan for drug discovery in rare pediatric neurodegenerative disease.

作者信息

Kerkovich Danielle, Drew Amy

出版信息

Cerebrum. 2011 Jul;2011:11. Epub 2011 Jul 21.

PMID:23447780
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3574766/
Abstract

There are currently no cures for neurodegenerative diseases, including Batten disease, a rare and fatal disorder affecting young children. While researchers have made headway in preventing genetic disorders through preconception carrier screenings and have found potential drug targets, the gap between basic research and clinical treatment development remains. To overcome this gap, write authors Dr. Danielle Kerkovich and Amy Drew, researchers in academia and the pharmaceutical industry, supported by government agencies and nonprofit institutions, must come together to share expertise and promote translational research.

摘要

目前,包括巴顿病在内的神经退行性疾病尚无治愈方法。巴顿病是一种影响幼儿的罕见致命疾病。虽然研究人员通过孕前携带者筛查在预防遗传疾病方面取得了进展,并发现了潜在的药物靶点,但基础研究与临床治疗开发之间的差距仍然存在。为了弥合这一差距,本文作者丹妮尔·克尔科维奇博士和艾米·德鲁写道,学术界和制药行业的研究人员在政府机构和非营利机构的支持下,必须携手合作,分享专业知识,促进转化研究。

相似文献

1
Designing a plan for drug discovery in rare pediatric neurodegenerative disease.设计罕见小儿神经退行性疾病的药物研发计划。
Cerebrum. 2011 Jul;2011:11. Epub 2011 Jul 21.
2
Child and adolescent psychopharmacology in the new millennium: a workshop for academia, industry, and government.新千年的儿童和青少年精神药理学:面向学术界、产业界和政府的研讨会
J Am Acad Child Adolesc Psychiatry. 2006 Mar;45(3):261-270. doi: 10.1097/01.chi.0000194568.70912.ee.
3
Guidelines, editors, pharma and the biological paradigm shift.指南、编辑、制药行业与生物学范式转变
Mens Sana Monogr. 2007 Jan;5(1):27-30. doi: 10.4103/0973-1229.32176.
4
Barriers to Alzheimer disease drug discovery and development in academia.学术界在阿尔茨海默病药物研发方面面临的障碍。
Alzheimer Dis Assoc Disord. 2002;16 Suppl 1:S18-28. doi: 10.1097/00002093-200200001-00004.
5
Open for collaboration: an academic platform for drug discovery and development at SciLifeLab.开放合作:斯克利普斯生命实验室的药物发现和开发学术平台。
Drug Discov Today. 2016 Oct;21(10):1690-1698. doi: 10.1016/j.drudis.2016.06.026. Epub 2016 Jun 29.
6
[Activity of NTDs Drug-discovery Research Consortium].[被忽视热带病药物研发联盟的活动]
Yakugaku Zasshi. 2016;136(2):231-6. doi: 10.1248/yakushi.15-00233-4.
7
A meeting of minds: interdisciplinary research in the health sciences in Canada.思想的交汇:加拿大健康科学领域的跨学科研究
CMAJ. 2006 Sep 26;175(7):763-71. doi: 10.1503/cmaj.060783.
8
Bridging the translational gap: collaborative drug development and dispelling the stigma of commercialization.弥合转化差距:合作开展药物研发并消除商业化的污名化现象。
Drug Discov Today. 2016 Feb;21(2):299-305. doi: 10.1016/j.drudis.2015.10.013. Epub 2015 Nov 6.
9
Funding resources for rare disease research.罕见病研究的资金来源。
Biochim Biophys Acta. 2013 Nov;1832(11):1910-2. doi: 10.1016/j.bbadis.2013.04.016. Epub 2013 Apr 19.
10
Helping science and drug development to succeed through pharma-academia partnerships: Yale Healthcare Conference 2013.通过药企-学术合作助力科学和药物研发成功:2013 年耶鲁医疗保健会议。
Yale J Biol Med. 2013 Sep 20;86(3):429-32. eCollection 2013 Sep.

引用本文的文献

1
Enabling Anyone to Translate Clinically Relevant Ideas to Therapies.让任何人都能将具有临床相关性的想法转化为治疗方法。
Pharm Res. 2017 Jan;34(1):1-6. doi: 10.1007/s11095-016-2039-5. Epub 2016 Sep 12.

本文引用的文献

1
The year's new drugs & biologics, 2010.2010年年度新药与生物制品
Drugs Today (Barc). 2011 Jan;47(1):27-51. doi: 10.1358/dot.2011.47.1.1587820.
2
Carrier testing for severe childhood recessive diseases by next-generation sequencing.下一代测序技术在严重儿童隐性疾病中的携带者检测
Sci Transl Med. 2011 Jan 12;3(65):65ra4. doi: 10.1126/scitranslmed.3001756.
3
Bridging the Valley of Death of therapeutics for neurodegeneration.弥合神经退行性疾病治疗学的死亡谷。
Nat Med. 2010 Nov;16(11):1227-32. doi: 10.1038/nm.2222. Epub 2010 Sep 21.
4
A knock-in reporter mouse model for Batten disease reveals predominant expression of Cln3 in visual, limbic and subcortical motor structures.Batten 病的敲入报告基因小鼠模型显示 Cln3 主要在视觉、边缘和皮质下运动结构中表达。
Neurobiol Dis. 2011 Feb;41(2):237-48. doi: 10.1016/j.nbd.2010.09.011. Epub 2010 Sep 25.
5
Partnership between academia and industry for drug discovery in Alzheimer's disease.学术界与产业界在阿尔茨海默病药物研发方面的合作。
Alzheimers Dement. 2008 Mar;4(2):80-8. doi: 10.1016/j.jalz.2008.02.004.
6
Translational research: crossing the valley of death.转化医学研究:跨越死亡谷。
Nature. 2008 Jun 12;453(7197):840-2. doi: 10.1038/453840a.
7
Progress towards understanding disease mechanisms in small vertebrate models of neuronal ceroid lipofuscinosis.在神经元蜡样脂褐质沉积症的小型脊椎动物模型中,对疾病机制的理解取得的进展。
Biochim Biophys Acta. 2006 Oct;1762(10):873-89. doi: 10.1016/j.bbadis.2006.08.002. Epub 2006 Aug 10.
8
Developing drugs for developing countries.为发展中国家研发药物。
Health Aff (Millwood). 2006 Mar-Apr;25(2):313-24. doi: 10.1377/hlthaff.25.2.313.
9
Current state of clinical and morphological features in human NCL.人类神经元蜡样脂褐质沉积症的临床和形态学特征现状
Brain Pathol. 2004 Jan;14(1):61-9. doi: 10.1111/j.1750-3639.2004.tb00499.x.
10
Survey of unlicensed and off label drug use in paediatric wards in European countries. European Network for Drug Investigation in Children.欧洲国家儿科病房中未获许可及未按说明书用药情况调查。欧洲儿童药物调查网络。
BMJ. 2000 Jan 8;320(7227):79-82. doi: 10.1136/bmj.320.7227.79.